Core Viewpoint - The innovative pharmaceutical sector in China is experiencing significant growth, with companies like Sanofi and others seeing substantial stock price increases, indicating a positive market trend for innovative drugs [1] Industry Summary - The Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, focusing on innovation over generic drugs and enhancing international market capabilities [1] - The innovative drug sector has opened new growth avenues for Chinese pharmaceutical companies, reflecting a long-term positive development trend [1] Company Summary - Companies such as Sanofi, Shuyitai, Zexing Pharmaceutical, and Yifang Bio have seen stock price increases of over 10%, with Sanofi reaching a 20% limit up [1] - The surge in stock prices is indicative of the market's confidence in the potential of innovative drugs and their commercialization prospects [1]

Core Viewpoint - The innovative drug concept stocks experienced a significant rise on October 31, with multiple companies reaching notable gains in their stock prices [1]. Group 1: Stock Performance - Sangfor Health (三生国健) saw a 20% increase, reaching a price of 72.96 [2] - Shuyou Pharmaceutical (舒泰神) rose by 14.29%, with a current price of 36.47 [2] - TuoJing Life (透景生命) increased by 11.97%, priced at 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69%, now at 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) rose by 11.06%, with a price of 99.18 [2] - Rongchang Biotechnology (荣昌生物) increased by 10.87%, priced at 98.30 [2] - Other notable increases include Hite Biotechnology (海特生物) at 10.33% and Weili Chemical (微粒化工艺物) at 10.19% [2]. Group 2: Hong Kong Market Performance - In the Hong Kong market, Fosen Pharmaceutical (福森药业) surged by 53.62%, reaching a price of 1.060 [3] - Yingtu Biotechnology (映图生物-B) increased by 12.44%, priced at 318.200 [3] - Yaojie Ankang (药捷安康-B) rose by 9.45%, with a current price of 190.000 [3] - Other companies such as Xinda Biopharmaceutical (信达牛物) and Jinfang Pharmaceutical (劲方医药) also saw increases of 8.18% and 8.05%, respectively [3].

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index at 3966.25 points, slightly down by 0.52%, while a total trading volume of 1,158.735 billion yuan has been recorded, indicating active market participation [1]. Group 1: Market Performance - The Shanghai Composite Index is currently above the annual line, reflecting a stable market condition despite a minor decline [1]. - A total of 129 A-shares have surpassed the annual line today, indicating a positive trend for many stocks [1]. Group 2: Individual Stock Performance - Notable stocks with significant deviation rates above the annual line include: - Zhong An Ke (600654) with a deviation rate of 7.81% and a daily increase of 9.88% [1]. - Ba Fang Shares (603489) with a deviation rate of 7.55% and a daily increase of 9.99% [1]. - Zejing Pharmaceutical (688266) with a deviation rate of 6.52% and a daily increase of 9.76% [1]. - Stocks with smaller deviation rates that have just crossed the annual line include ST Xiangxue, Keli'er, and Nanda Environment, indicating a cautious recovery [1].

2025年10月31日，泽璟制药(688266.SH)发布2025年第三季报。截至2025年10月30日，共有129个机构投 资者披露持有泽璟制药A股股份，合计持股量达8125.19万股，占泽璟制药总股本的30.69%。其中，前 十大机构投资者包括宁波泽奥创业投资合伙企业(有限合伙)、中国工商银行股份有限公司-中欧医疗健康 混合型证券投资基金、中国建设银行股份有限公司-工银瑞信前沿医疗股票型证券投资基金、中国建设 银行股份有限公司-汇添富创新医药主题混合型证券投资基金、宁波璟晨投资合伙企业(有限合伙)、中国 建设银行股份有限公司-富国精准医疗灵活配置混合型证券投资基金、香港中央结算有限公司、广发医 疗保健股票A、汇添富医疗服务灵活配置混合A、富国医药创新股票A，前十大机构投资者合计持股比 例达19.15%。相较于上一季度，前十大机构持股比例合计下跌了1.07个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计71个，主要包括富国医药创新股票A、富国优化 增强债券A/B、嘉实互融精选股票A、平安医疗健康混合A、东方红医疗升级股票发起A等，持股增加占 比达3.65%。本期较上一季度持股减少的公募基金共计4 ...

格隆汇10月30日丨泽璟制药(688266.SH)发布三季报，2025年前三季度实现营业总收入5.93亿元，同比增 长54.49%；归属母公司股东净利润-9341.62万元，较上年同期亏损减少448.68万元；基本每股收益 为-0.35元。 ...

重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 证券代码：688266 证券简称：泽璟制药 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 217,789,855.47 | 51.85 | 593,440,129.02 | 54.49 | | 利润总额 | -20,904,645.94 | 不适用 | -9 ...

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020 [1] - The company's main business involves the research, production, and sales of chemical new drugs and biological new drugs, with 99.97% of revenue coming from pharmaceuticals [1] Fund Holdings - One fund under Industrial Bank, the Industrial Medical Care A (011466), holds 143,000 shares of Zai Jian Pharmaceutical, unchanged from the previous period, representing 4% of the fund's net value [2] - The fund has a total size of 261 million CNY and has achieved a year-to-date return of 24.05% [2] - The fund manager, Chen Xu, has been in position for 4 years and 238 days, with the best and worst fund returns during his tenure being -19.16% and -21.01%, respectively [2]

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a trading volume of 279 million CNY and a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020. The company focuses on the research, production, and sales of chemical and biological new drugs [1] - The main revenue composition of the company is 99.97% from pharmaceuticals, 0.02% from pharmaceutical intermediates and raw materials, and 0.00% from asset leasing [1] Fund Holdings - A fund under Bank of China Securities holds Zai Jian Pharmaceutical as one of its top ten holdings. The fund, Zhongyin Securities Health Industry Mixed Fund (002938), reduced its holdings by 4,000 shares in the third quarter, maintaining 128,000 shares, which accounts for 9.08% of the fund's net value, ranking it as the third-largest holding [2] - The fund has a total size of 159 million CNY and has achieved a year-to-date return of 39.48%, ranking 2223 out of 8152 in its category. Over the past year, it has returned 28.41%, ranking 3260 out of 8038, and since inception, it has returned 134.28% [2] Fund Manager Information - The fund manager of Zhongyin Securities Health Industry Mixed Fund (002938) is Li Mingwei, who has been in the position for 2 years and 252 days. The fund's total asset size is 159 million CNY, with the best and worst returns during his tenure being -5.4% [3]

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. will hold a Q3 2025 earnings presentation on November 5, 2025, to discuss its operational results and financial status for the third quarter of 2025, allowing investors to engage in Q&A sessions [2][3][6]. Group 1: Meeting Details - The earnings presentation will take place on November 5, 2025, from 16:00 to 17:00 [6][7]. - The meeting will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [3][6]. - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center website [5][6]. Group 2: Investor Participation - Investors can submit questions from October 31, 2025, to November 4, 2025, before 16:00 through the Roadshow Center or via the company's email [2][8]. - The company will address commonly asked questions during the earnings presentation, within the limits of information disclosure [3][8]. Group 3: Participants - Key participants in the meeting will include the Chairman and General Manager Zelin Sheng, along with other executives and independent directors [4].

证券代码：688266 证券简称：泽璟制药 公告编号：2025-042 苏州泽璟生物制药股份有限公司 关于召开 2025 年度第三季度业绩说明会的公告 苏州泽璟生物制药股份有限公司（以下简称"公司"）将于 2025 年 10 月 31 日发布公司《2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 5 日下午 16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点、方式 （一）会议召开时间：2025 年 11 月 5 日（星期三）下午 16:00-17:00 ● 会议召开时间：2025 年 11 月 5 日（星期三）16:00-17:00 ● 会议召开地点：上证路演中心（http://roadshow.sseinfo.com） ● 会议召开方式：上证路演中心网络 ...